Cargando…

Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study

Hemophilia is a congenital bleeding disorder caused by low levels of clotting factor VIII or IX. The life expectancy of people with hemophilia (PWH) has increased with the availability of clotting factor concentrates. At the same time, the incidence of cardiovascular disease (CVD) has increased; in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Der Valk, Paul, Makris, Michael, Fischer, Kathelijn, Tait, Robert C., Chowdary, Pratima, Collins, Peter W., Meijer, Karina, van Vulpen, Lize F. D., Mauser-Bunschoten, Eveline, Schutgens, Roger E. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945305/ https://www.ncbi.nlm.nih.gov/pubmed/34879394 http://dx.doi.org/10.1182/bloodadvances.2021005260

Ejemplares similares

Catheter Ablation for Atrial Fibrillation in Patients with Hemophilia or von Willebrand Disease
por: van der Valk, Paul R., et al.
Publicado: (2019)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Liver‐related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders
por: Isfordink, Cas J., et al.
Publicado: (2022)

Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
por: Isfordink, Cas J., et al.
Publicado: (2021)

Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study
por: Schep, Sarah J., et al.
Publicado: (2020)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
por: Ay, Cihan, et al.
Publicado: (2023)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
por: van Balen, Erna C., et al.
Publicado: (2022)

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A
por: Schep, Sarah J., et al.
Publicado: (2021)

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results
por: Königs, Christoph, et al.
Publicado: (2022)

Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study
por: van Galen, Karin P.M., et al.
Publicado: (2017)

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
por: Traets, Marissa J.M., et al.
Publicado: (2020)

Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
por: Hassan, Shermarke, et al.
Publicado: (2021)

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
por: Hassan, Shermarke, et al.
Publicado: (2020)

Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
por: Versloot, Olav, et al.
Publicado: (2022)

Movement behavior in hemophilia—from medicalized training approaches toward an active lifestyle
por: Blokzijl, Johan, et al.
Publicado: (2021)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
por: Dickinson, Michael, et al.
Publicado: (2021)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

Multinational survey on the preferred approach to management of Barrett’s esophagus in the Asia-Pacific region
por: Kew, Guan Sen, et al.
Publicado: (2021)

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
por: Huisman, W., et al.
Publicado: (2022)

Gene Therapy in Hemophilia: From Hype to Hope
por: Schutgens, Roger
Publicado: (2018)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers
por: Gooding, Richard, et al.
Publicado: (2021)

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study
por: Malec, Lynn, et al.
Publicado: (2023)

Outcomes of Early Versus Late Tracheostomy in Patients With COVID-19: A Multinational Cohort Study
por: Harrell Shreckengost, Constance S., et al.
Publicado: (2022)

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
por: van Doesum, Jaap A., et al.
Publicado: (2023)

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies
por: Campbell, Belinda A., et al.
Publicado: (2023)

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
por: Ansell, Stephen M., et al.
Publicado: (2023)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
por: Fox, Christopher P., et al.
Publicado: (2021)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h1eb82rrg8pj54vs75c4c4cmpe